Is prostate cancer screening worthy in southern European male populations? A case study in Eleusina, Greece.

Objective: To investigate the frequency of PSA-detected prostate cancer among non-symptomatic Greek males.

Methods: A prospective study on prostate cancer (PC) screening was performed in a representative sample of asymptomatic Greek males aged 40-75 years in Eleusina, (Greece) between January and November 2001. Indication for prostate biopsy was a PSA value above 3.

Brucella melitensis: a rarely suspected cause of infections of genitalia and the lower urinary tract.

We examined the clinical presentation and outcome of Brucellar infections of genitalia and the lower urinary tract through a review of the medical records of 10 cases of male patients with brucellar infections of the genitalia and lower urinary tract. The mean age of the patients with brucellosis was 49.2, (median 52, range 15-77 years).

Cystic nephroma: a case report and review of the literature.

Background: The spectrum of cystic renal neoplasms includes both benign and malignant tumors and the order is as follows: benign multilocular cyst, multilocular cystic renal cell cancer and cystic renal cell cancer. Gross similarities among multicystic tumors of the kidney may cause conflict in the diagnosis and treatment of these lesions.

Results: We report a 53-year old male patient who presented with a mild persistent left flank pain and a painful left renal mass.

Hyperprolactinaemia due to hypothalamic-pituitary disease or drug-induced in patients with erectile dysfunction.

One hundred and sixty-five patients with erectile dysfunction were assessed at the Athens Medical Sex Institute: 60 men (36.4%) considered their condition as organic, 52 (31.5%) rated it as mostly psychogenic, 45 (27.

Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml).

Whether serum testosterone (T) can become an adjunct test able to validate the PSA-weighted risk of prostate cancer (PR.CA) in the "grey" diagnostic area (PSA =3.0 to <10.